ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 1672 • ACR Convergence 2024

    The Evaluation of SLE Outcome Measures in Telemedicine

    Maya Souvignier1, Cynthia Aranow2, Anca Askanase1, Mimi Kim3, Diane Kamen4, Cristina Arriens5, Leila Khalili1, Wei Tang6, Maria Dall'Era7 and Meggan Mackay8, 1Columbia University Medical Center, New York, NY, 2Feinstein Institutes for Medical Research, New York, NY, 3Albert Einstein College of Medicine, New York, NY, 4Medical University of South Carolina, Charleston, SC, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Westchester Medical Center, Valhalla, 7UCSF, Corte Madera, CA, 8Feinstein Institutes for Medical Research, Manhasset, NY

    Background/Purpose: Telemedicine (TM) has been integral to rheumatology care since the Covid-19 pandemic; evidence suggests high acceptance, satisfaction, and feasibility. However, due to the complexity…
  • Abstract Number: 1754 • ACR Convergence 2024

    Comparing the Molecular Landscape of the CAR-T Cell and Rituximab Mediated Remission in Systemic Lupus Erythematosus

    Panagiotis Garantziotis1, Ioannis Parodis2, George Bertsias3, Dimitrios Boumpas4 and Georg Schett5, 1Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, 2Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, 3Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, 44th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, Athens, Greece, 5Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Despite the negative clinical trials, B-cell depletion by antibodies has been used off-label to treat refractory Systemic Lupus Erythematosus (SLE). Emerging evidence shows that CD19…
  • Abstract Number: 1794 • ACR Convergence 2024

    Biobehavioral Basis and Outcomes of Cognitive Dysfunction in Childhood Systemic Lupus Erythematosus

    Hanne van der Heijden1, Andrea Knight2, Itamar Ronen3, Gabrielle Alonzi4, Kyle McBrearty4, Aditi Deokar4, Joseph Gonzalez-Heydrich4, Joyce Chang4 and Jaymin Upadhyay5, 1Boston Children's Hospital Harvard Medical School, Boston, MA, 2Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 3Brighton and Sussex Medical School, University of Sussex, Brighton, UK, Brighton, United Kingdom, 4Boston Children's Hospital, Boston, MA, 5Boston Children's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Cognitive dysfunction (CD) in childhood-onset SLE (cSLE) is undertreated yet profoundly impacts lifelong health-related quality of life. Investigating CD in cSLE is crucial, given…
  • Abstract Number: 1842 • ACR Convergence 2024

    Development of Next Generation CAR T Cell Therapy for the Off-the-shelf Treatment of Autoimmune Diseases Without Conditioning Chemotherapy

    John Goulding1, John Reiser2, Alison O'Connor1, Bryan Hancock1, Jonatan Tuncel1, Brian Groff1, Rina Mbofung1, Daniel Morales-Mantilla1, Allan Williams1, Dan Lu1, Bi-Huei Yang1, Eigen Peralta1, Alma Gutierrez1, Miguel Meza1, Betsy Rezner1, Amanda Sims1, Alec Witty1, Yijia Pan1, Mark Jelcic1, Shohreh Sikaroodi1, Matthew Denholtz1, Tom Lee1, Anil Bagri1, Lilly Wong1, Jode Goodridge1 and Bahram Valamehr1, 1Fate Therapeutics Inc., San Diego, CA, 2Fate Therapeutics Inc, San Diego, CA

    Background/Purpose: Developed initially as a novel strategy to treat B cell malignancies, chimeric antigen receptor (CAR) T cells have now been used to treat multiple…
  • Abstract Number: 2120 • ACR Convergence 2024

    EvaluationofBone Mineral Densityand Trabecular Bone Score in JuvenileSystemicLupusErythematosusPatientsUsing Dual-Energy X-rayAbsorptiometry

    BEATRIZ ROSA1, Melissa Fraga1, Erica Barbosa1, Jade Dib Fernandez2, Marcelo Pinheiro3 and Maria Teresa Terreri4, 1Universidade Federal de São Paulo, São Paulo, SP, Brazil, 2UNIFESP-EPM, São Paulo, SP, Brazil, 3UNIFESP/ EPM, São Paulo, SP, Brazil, 4UNIFESP, São Paulo, SP, Brazil

    Background/Purpose: Juvenile Systemic Lupus Erythematosus (jSLE) is a multisystem inflammatory disease associated with bone mass loss. This loss can be evaluated by using the bone…
  • Abstract Number: 2379 • ACR Convergence 2024

    Causal Proteomics-Assisted Machine Learning Model Enhances Flare Risk Prediction in Systemic Lupus Erythematosus

    Liying Chen1, Ou Deng2, Ruichen Cong2, Dingqi Lu3, Ting Fang1, Mei Chen1, Runrun Zhang4 and Xinchang Wang3, 1Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China (People's Republic), 2Graduate School of Human Sciences, Waseda University, Mikajima, Japan, 3Department of Rheumatology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China (People's Republic), 4The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China (People's Republic)

    Background/Purpose: Objectives: Systemic lupus erythematosus (SLE) is an autoimmune disease marked by unpredictable flares. However, no flare risk prediction model has been developed for Asian…
  • Abstract Number: 2397 • ACR Convergence 2024

    Increase of IL10 and IFNa2 Are Associated to Clinical Activity in Systemic Lupus Erythematous Patients

    Elena Grau García1, Marta De la Rubia Navarro2, Samuel Leal Rodriguez1, José Ivorra-Cortés3, Carmen Riesco Barcena4, Anderson Huaylla Quispe4, Laura Mas Sánchez5, Pablo Muñoz Martínez6, Daniel Ramos Castro4, Alba Torrat noves7, Iago Alcantara Alvarez2, Belén Villanueva Mañés2, Miguel Simeo Vinaixa2, Andrés Pérez Hurtado4 and Jose A Román-Ivorra8, 1HUP La Fe, Valencia, Spain, 2Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 3Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, 4Rheumatology Department. HUP La Fe, Valencia, Spain, 5Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, 6Hospital Universitario y Politècnico La Fe, Sagunto, Spain, 7Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, 8Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain

    Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by deregulation of cytokine production. Interferon (IFN) is a proinflamatory cytokine considered as a key…
  • Abstract Number: 2415 • ACR Convergence 2024

    Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network

    Nehad Soloman1, Jawad Bilal2, Romy Cabacungan3, Scott Milligan4, Andrew Sharobeem5, John Tesser6 and Henry Leher7, 1Arizona Arthritis & Rheumatology Associates, P.C., Glendale, AZ, 2University of Arizona, Tucson, AZ, 3Arizona Arthritis & Rheumatology Associates, P.C., Tucson, AZ, 4Trio Health, Louisville, CO, 5AARA, Peoria, AZ, 6Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 7Aurinia Pharma, Stowe, VT

    Background/Purpose: Lupus nephritis (LN) has been estimated to develop in up to 40% of all patients with systemic lupus erythematosus (SLE), with higher rates in…
  • Abstract Number: 2432 • ACR Convergence 2024

    In Vitro and In Vivo Evidence of the Steroid-Sparing Potential of Afimetoran, an Equipotent Toll-Like Receptor 7/8 Dual Antagonist

    Shailesh Dudhgaonkar1, Siva Subramani2, Puneet Chopra2, Anjuman Rudra2, Sourabha Palachandra2, Nikita Sanjay Bhatt2, Veeresh Pabbala2, Sabariya Selvam2, Mobeen Shaik2, Amit Anand2, Benjamin King3, Kristina Chadwick3, Alaric Dyckman3, Qihong Zhao3, Frédéric Baribaud3, Ramya Janardhana4 and Vineeta Shobha5, 1Bristol Myers Squibb, Bangalore, India, 2Biocon BMS Research Center, Syngene International Ltd, Bangalore, India, 3Bristol Myers Squibb, Princeton, NJ, 4St. John’s Medical College, Bengaluru , India, Bangalore, India, 5St. John’s Hospital, Bangalore, India

    Background/Purpose: SLE is a highly heterogeneous chronic autoimmune disease, with glucocorticoid therapy as the standard of care. SLE control requires high steroid doses; long-term use…
  • Abstract Number: 2577 • ACR Convergence 2024

    Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: Results Through 104 Weeks in a Long-Term Extension Study

    Joan Merrill1, Amit Saxena2, Martin Aringer3, Yoshiya Tanaka4, Xiaofeng Zeng5, Peter Wung6, Ling Cheng6, Thao Doan6, Shelly Kafka6, David DCruz7 and Kristin D'Silva6, 1Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, 2NYU Grossman School of Medicine, New York, NY, 3University Medical Center and Faculty of Medicine, TU Dresden, Dresden, Germany, 4Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 5Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China, 6AbbVie Inc., North Chicago, IL, 7The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: ABBV-599 (a combination of a selective Bruton’s tyrosine kinase inhibitor, elsubrutinib [ELS], and a selective Janus kinase inhibitor, upadacitinib [UPA]) targets a spectrum of…
  • Abstract Number: 2662 • ACR Convergence 2024

    In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases

    Laurie Beitz1, Maura Parker1, Justin Ulrich-Lewis1, Kristen Mittelsteadt1, Rebecca Gottschalk1, Chris Nicolai1, Jim Qin1, Andrew Scharenberg1, Ryan Larson1, Byoung Ryu1, Eric Cavanaugh2, Weiliang Tang1, Seungjin Shin1, Kelsey Lynch1 and Hans-Peter Kiem2, 1Umoja Biopharma, Seattle, WA, 2Fred Hutch Cancer Research Center, Seattle, WA

    Background/Purpose: CAR T cell therapy promises to revolutionize the treatment of hematologic malignancies, and more recently has generated early data that it may afford long…
  • Abstract Number: 0011 • ACR Convergence 2024

    Preclinical Manufacturability and Activity of KYV-102 from Patients with Systemic Lupus Erythematosus Using Ingenui-T: A Rapid, Autologous Chimeric Antigen Receptor T-Cell Manufacturing Solution Utilizing Whole Blood

    Brandon Kwong1, Daniel Anaya1, Soo Park2, Sunetra Biswas2, Jeevitha Jeevan2, Jesus Banuelos2, Madison Strobach2, Nicole Khoshnoodi1, Timothy Klasson1, Santiago Foos-Russ1, Jennifer Zeng1, Candice Gibson3, Jazmin Bravo2, Simone Sandoval1, Shouvonik Sengupta1, Shairaz Shah1, Tom Van Blarcom2 and Karen Walker2, 1Kyverna Therapeutics, Inc., Emeryville, CA, 2Kyverna Therapeutics, Inc., Emeryville, 3Kyverna Therapeutics, Inc., Emerybille

    Background/Purpose: Apheresis in conventional chimeric antigen receptor (CAR) T-cell therapy can be burdensome, and conventional manufacturing cultures apheresis-derived cells for 7-14 days, leading to a…
  • Abstract Number: 0109 • ACR Convergence 2024

    Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Rohan Willis1, Anne Tebo2, Leslie Skeith3, Nina Kello4, H Michael Belmont5, Paul Fortin6, Guilherme Ramires de Jesús7, David Branch8, Michelle Petri9, Jason Knight10, Reyhan Kose Cobanoglu11, Maria Laura Bertolaccini12, Hannah Cohen13, Robert Roubey14, Doruk Erkan15 and Danieli Andrade16, and on behalf of APS ACTION, 1University of Texas Medical Branch, Galveston, TX, 2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 3University of Calgary, Calgary, ON, Canada, 4Northwell Health, Brooklyn, NY, 5NYU School of Medicine, New York, NY, 6Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 7Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 8University of Utah and Intermountain Healthcare, Salt Lake City, UT, 9Johns Hopkins University School of Medicine, Timonium, MD, 10University of Michigan, Ann Arbor, MI, 11Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, 12King's College London, London, United Kingdom, 13University College London Hospitals NHS Foundation Trust, London, United Kingdom, 14Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 15Hospital for Special Surgery, New York, NY, 16University of São Paulo, São Paulo, SP, Brazil

    Background/Purpose: Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are characterized by heterogenous clinical presentations, driven by autoantibodies; patients with SLE develop APS more often…
  • Abstract Number: 0181 • ACR Convergence 2024

    Integrated Multidisciplinary Lupus Social Work Program to Manage Social Determinants of Health in SLE and Lupus Nephritis – Preliminary Results

    Kimberly DeQuattro1, Stephanie DeVaughn2, Andrew Kanoff3 and Abdallah Geara1, 1University of Pennsylvania, Philadelphia, PA, 2Uniersity of Pennsylvania, Pennsylvania, 3University of Pennsylvania, Philadelphia, PA, Philadelphia, PA

    Background/Purpose: Minoritized individuals with systemic lupus erythematosus (SLE) experience social determinants of health (SDOH) challenges that affect access to care and increase the risk for…
  • Abstract Number: 0212 • ACR Convergence 2024

    Costs of Hospitalization in Patients with SLE: An Analysis of the National Inpatient Sample

    Brandon Blau1, Kelsey Gripp1, Catherine MacLean2 and Bella Mehta2, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) is associated with significant health care utilization, medical costs, and increased risk of hospitalization. We aimed to characterize the reasons…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 150
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology